Cargando…
MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis
SIMPLE SUMMARY: MET exon 14 splice-site mutations occur in ~3–4% of lung adenocarcinoma cases, defining a cohort of patients which might benefit from anti-MET targeted therapy. Such therapies have yielded mixed results, however, pointing to the need for better treatment design. Our study sought to a...
Autores principales: | Lu, Daniel, Nagelberg, Amy, Chow, Justine LM, Chen, Yankuan T, Michalchuk, Quentin, Somwar, Romel, Lockwood, William W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946549/ https://www.ncbi.nlm.nih.gov/pubmed/35326531 http://dx.doi.org/10.3390/cancers14061378 |
Ejemplares similares
-
Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer
por: Suzawa, Ken, et al.
Publicado: (2019) -
Pan-cancer pervasive upregulation of 3′ UTR splicing drives tumourigenesis
por: Chan, Jia Jia, et al.
Publicado: (2022) -
Devil in the detail: MET overexpression fails as surrogate marker for MET exon 14 splice site mutations in NSCLC
por: Strickland, Matthew R., et al.
Publicado: (2020) -
Systemic muscle wasting and coordinated tumour response drive tumourigenesis
por: Newton, Holly, et al.
Publicado: (2020) -
Gastrointestinal malignancies harbor actionable MET exon 14 deletions
por: Lee, Jeeyun, et al.
Publicado: (2015)